Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. Kato K, et al. Among authors: kawakami h. Esophagus. 2023 Apr;20(2):291-301. doi: 10.1007/s10388-022-00970-1. Epub 2022 Nov 19. Esophagus. 2023. PMID: 36401133 Free PMC article. Clinical Trial.
Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. Siena S, et al. Among authors: kawakami h. Nat Commun. 2025 Jan 15;16(1):704. doi: 10.1038/s41467-025-56170-9. Nat Commun. 2025. PMID: 39814812 Free article. No abstract available.
Safety and Efficacy of Imeglimin for Type 2 Diabetes Mellitus in Patients With Heart Failure.
Nishikawa T, Higaki A, Kurokawa K, Yoshimoto K, Horie R, Nakao Y, Fujisawa T, Miyazaki S, Akazawa Y, Miyoshi T, Kawakami H, Higashi H, Tamaki S, Nishimura K, Inoue K, Ikeda S, Yamaguchi O. Nishikawa T, et al. Among authors: kawakami h. In Vivo. 2025 Jan-Feb;39(1):375-380. doi: 10.21873/invivo.13838. In Vivo. 2025. PMID: 39740918 Free PMC article.
Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403).
Sugimoto N, Kawada J, Oka Y, Ueda S, Murakami K, Nishikawa K, Kurokawa Y, Fujitani K, Kawakami H, Endo S, Sakai D, Shimokawa T, Satoh T. Sugimoto N, et al. Among authors: kawakami h. Anticancer Res. 2025 Jan;45(1):307-313. doi: 10.21873/anticanres.17418. Anticancer Res. 2025. PMID: 39740851 Clinical Trial.
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS.
Komori A, Hironaka S, Kadowaki S, Mitani S, Furuta M, Kawakami T, Makiyama A, Takegawa N, Sugiyama K, Hirano H, Ando T, Matsushima T, Chida A, Kashiwada T, Komoda M, Matsumoto T, Oda H, Yabusaki H, Kawakami H, Yamazaki K, Boku N, Hyodo I, Yoshimura K, Muro K; West Japan Oncology Group (WJOG). Komori A, et al. Among authors: kawakami h. Gastric Cancer. 2024 Dec 31. doi: 10.1007/s10120-024-01579-2. Online ahead of print. Gastric Cancer. 2024. PMID: 39738793
1,506 results